麻豆传媒

Now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered the details behind the virus鈥檚 unique ability to cross the placental barrier and expose the fetus to a range of birth defects that often go beyond microcephaly to include eye and joint injury, and even other types of brain damage.

The new study, led by TSRI Associate Professor Hyeryun Choe, was published online ahead of print this week in the journal Proceedings of the National Academy of Sciences.

How Zika virus crosses the placental barrier, while other closely related viruses in the flavivirus family including dengue and West Nile viruses do not, has puzzled researchers since the crisis began some two years ago in Brazil.

Obstacles to reaching the fetal brain are substantial鈥攁 virus must move from the mother鈥檚 blood into fetal circulation, which is separated by placental barrier cells designed to prevent that very occurrence.

The researchers found that human umbilical endothelial cells, derived from four donors in the study, proved far more susceptible to Zika infection than to other viruses, with viral counts as much as a hundred or thousand times higher than West Nile or dengue virus. The new research also suggests that Zika virus learned to exploit something of a secret passage, a cell surface molecule known as AXL, while West Nile and dengue viruses did not.

鈥淶ika uses AXL to efficiently slip past one of the major barrier cell types in the placenta: fetal endothelial cells, which are the gateway to access fetal circulation,鈥� said Choe.

What may help make the Zika virus particularly infectious in cells that other flaviviruses can't infect, said TSRI Research Associate Audrey Richard, a first author of the study, is that it profits from the built-in function of AXL. 鈥淭he physiological function of AXL is to quench activated immune reactions, including the antiviral interferon response,鈥� said Richard. 鈥淏y using AXL, Zika virus catches two birds with one stone; it enters cells and also gains favorable environment for its replication inside the cells.鈥�

Zika is able to take advantage of AXL by binding to an intermediate molecule known as Gas6, which is present in blood and other bodily fluids. Gas6 acts as an active bridge between the virus and AXL by binding AXL on one end and the virus membrane on the other, helping the virus utilize AXL and gain entry to host cells.

These differences may help explain why, among related viruses, only Zika can efficiently access and infect the fetal bloodstream.

鈥淲e don鈥檛 yet understand why Zika virus uses AXL and the others don鈥檛,鈥� Choe added. 鈥淭he common belief is that all flaviviruses have similar structures, but our findings suggest that Zika virus may have a different average population structure than others. This has significant scientific and clinical implications.鈥�

鈥淪tructural studies show that most of the infectious virion membrane is completely covered with viral proteins, which makes it difficult for Gas6 to bind to the Zika virus membrane underneath the protein shell,鈥� said TSRI Research Associate Byoung-Shik Shim, the study鈥檚 other first author. 鈥淗owever, flavivirus particles assume many asymmetric shapes and are in continuous dynamic motion, which likely exposes patches of the virion membrane. Our study suggests that Zika virus exposes enough membrane for Gas6 binding, whereas West Nile and dengue viruses do not.鈥�

The researchers also speculated on Zika virus鈥� pathology. AXL is also present in the blood-brain barrier, the eye-blood barrier and the testes鈥攚here it maintains integrity of the blood vessels and the functions of the testes. It may be used by Zika virus to infect those cells and may explain Zika virus鈥� ability to infect the fetal brain and eye and to transmit sexually.

In addition to Choe, Richard and Shim, other authors of the study, 鈥淎XL-Dependent Infection of Human Fetal Endothelial Cells Distinguishes Zika Virus from Other Pathogenic Flaviviruses,鈥� include Young-Chan Kwon, Yuka Otsuka, Kimberly Schmitt and Fatma Berri of TSRI; Rong Zhang and Michael S. Diamond of Washington University School of Medicine, St. Louis, MO.

The study was supported by start-up funds from the state of Florida and the National Institutes of Health (grants R01 AI110692, R01 AI073755 and R01AI101400).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists鈥攊ncluding two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine鈥攚ork toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see .